While the largest deal of the week, and certainly the one receiving the most attention, has been Actavis' expansion of its branded p...

Well, that flew by. Unlike the little elf in the video above (and if you don't know Nick Lowe, 'tis the season to make your acqua...

One month ago, as the government shut itself partially down, this column wondered if the IPO window might undergo a similar fate. Sinc...

We live in strange times. Venture capitalists, the traditional support for research-stage biopharmas, have been pulling back from early ...

It’s been another IPO-intensive couple of weeks here at FOTF HQ. We keep looking for other things to write about, but sometimes the faste...